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Abstract
Background: Phosphatidic acid (PA) is a diacyl-glycerophospholipid that acts as a signaling molecule in numerous
cellular processes. Recently, PA has been proposed to stimulate skeletal muscle protein accretion, but mechanistic
studies are lacking. Furthermore, it is unknown whether co-ingesting PA with other leucine-containing ingredients
can enhance intramuscular anabolic signaling mechanisms. Thus, the purpose of this study was to examine if oral
PA feeding acutely increases anabolic signaling markers and muscle protein synthesis (MPS) in gastrocnemius with
and without whey protein concentrate (WPC).
Methods: Overnight fasted male Wistar rats (~250 g) were randomly assigned to four groups: control (CON, n = 6-13),
PA (29 mg; n = 8), WPC (197 mg; n = 8), or PA +WPC (n = 8). Three hours post-feeding, gastrocnemius muscle was
removed for markers of Akt-mTOR signaling, gene expression patterns related to skeletal muscle mass regulation and
metabolism, and MPS analysis via the SUnSET method.
Results: Compared to CON rats, PA, WPC and PA +WPC resulted in a significant elevation in the phosphorylation of
mTOR (Ser2481) and rps6 (Ser235/236) (p < 0.05) in the gastrocnemius though there were no differences between the
supplemented groups. MPS levels in the gastrocnemius were significantly (p < 0.05) elevated in WPC versus CON rats,
and tended to be elevated in PA versus CON rats (p = 0.08), though MPS was less in PA +WPC versus WPC rats (p < 0.05)
in spite of robust increases in mTOR pathway activity markers in the former group. C2C12 myoblast data agreed with the
in vivo data herein showing that PA increased MPS levels 51 % (p < 0.001) phosphorylated p70s6k (Thr389) levels 67 %
(p < 0.001).
Conclusions: Our results are the first in vivo evidence to demonstrate that PA tends to increases MPS 3 h post-feeding,
though PA may delay WPC-mediated MPS kinetics within a 3 h post-feeding window.
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Background
Skeletal muscle growth is controlled by several intricate
processes dictated in large part by nutrient and intra-
muscular mechano-responsive factors [1]. To this end,
the mammalian target of rapamycin (mTOR) is thought
to be a nodal point for controlling skeletal muscle hyper-
trophy. While mTOR activation is complex, a simplistic
overview of this process is as follows [2]: a) mTOR
complex 1 (mTORC1), which is comprised of mTOR-
Raptor- mLST8, can be activated by muscle contraction
and nutritional factors; b) activated mTORC1 then acts
to phosphorylate and activate p70s6 kinase (p70s6k)
while hyper-phosphorylating eukaryotic initiation factor
4E (eIF4E)-binding proteins (4EBP-1/2); c) activated
p70s6k phosphorylates and activates ribosomal protein
s6 (rps6), while hyperphosphorylated 4EBP1/2 become
inactive thus facilitating ribosomal assembly; and d) ac-
tivated rps6 further increases ribosomal assembly via
enhanced 5’-cap-dependent messenger RNA (mRNA)
translation of selective genes. These aforementioned
processes ultimately result in an elevation in skeletal
muscle protein synthesis (MPS) and, if stimulated re-
petitively with resistance exercise and ample nutrition,
lead to an increase in skeletal muscle accretion.
Phosphatidic acid (PA) is a diacyl-glycerophospholipid
that is enriched in eukaryotic cell membranes and it can
act as a signaling lipid [3]. For instance, it has been
shown that PA regulates a wide array of cellular pro-
cesses including but not limited to proliferation, differ-
entiation, survival signaling, cytoskeletal rearrangement
and vesicular trafficking (reviewed in [4]). PA can also
elicit anabolic responses in cells. In this regard, a hall-
mark mechanistic study performed by Fang et al. [5]
demonstrated that PA activates mTOR by binding to the
FKBP12-rapamycin binding (FRB) domain on mTOR.
Follow-up studies by Hornberger et al. [6] revealed that
mechanical stretching of skeletal muscle promotes an
increase in intramuscular PA levels and this effect was
associated with the activation of mTOR signaling (e.g.
increased p70s6k phosphorylation), and that eccentric
contraction increases skeletal muscle PA levels which, in
turn, activate mTOR signaling [7]. More recent data
from Hornberger’s group suggests that the ζ isoform of
diacylglycerol kinase, which synthesizes intramuscular
PA via the phosphorylation of diacylglycerol, is largely
responsible for the increase in PA levels and the activa-
tion of mTOR signaling that occurs in response to
stretch [8]. However, others have suggested that PA does
not directly bind to mTOR, but rather activates the
MAP kinase pathway proteins Erk1/2 via its conversion
into lysophosphatidic acid (LPA) which ultimately results
in mTOR activation [9]. Likewise, others have shown
that PA binds to p70s6k to exhibit its biological effects
in an mTOR-independent fashion [10]. Notwithstanding,
and in spite of these divergent findings, there is ample
in vitro evidence to suggest that PA increases mTORC1
signaling.
Given the ability of biosynthesized PA to activate the
intramuscular mTORC1 signaling, there is intense inter-
est for the potential of PA supplementation to act as an
ergogenic/muscle-building aid. To this end, two recent
human studies supplemented participants with 750 mg
of soy-derived PA over an 8-week resistance training
period. Hoffman et al. [11] reported that PA supplemen-
tation increased whole-body lean body mass (LBM) by
1.7 kg, whereas the placebo group demonstrated no rela-
tive change in LBM (0.1 kg; p = 0.065 between groups).
Joy et al. [12] performed a similar 8-week study with
more participants and supervised training sessions, and
reported that soy-derived PA supplementation signifi-
cantly increased LBM by 2.4 kg, whereas the placebo
group demonstrated marginal increases in LBM (1.2 kg;
p < 0.05 between groups). Joy et al. also used an in vitro
approach to demonstrate that stimulating differentiated
myoblasts with soy-derived PA elicited over a 6-fold in-
crease in p70s6k (Thr389) phosphorylation which is in-
dicative of mTOR activation. While both studies suggest
that soy-derived PA supplementation is effective at aug-
menting resistance exercise-induced skeletal muscle
hypertrophy, neither study measured the effects of PA
on MPS levels and/or mTOR signaling events in vivo.
Likewise, it remains to be determined if other mTOR-
modulating ingredients (i.e., intact dietary protein
sources rich in L-leucine) provide a synergistic effect
with regards to activating mTOR and downstream
events related to increasing MPS. Leucine activates
mTOR through RAG GTPases which, in the presence
of leucine, bind to Raptor and increase mTORC1 com-
plex localization to vesicles to increase its kinase ac-
tivity [13]. PA is thought to independently activate
mTOR through competitive binding with the mTOR
inhibitor FKBP38; both which bind to the FRB domain
[14]. Thus, given that these are two modes whereby
mTORC1 kinase activity can be independently acti-
vated, it stands to reason that whey protein could
synergistically activate mTOR if co-ingested with PA.
Therefore, the purpose of this study was to examine
if PA acutely increases anabolic signaling markers and
muscle protein synthesis (MPS) in gastrocnemius with
and without whey protein concentrate (WPC) supple-
mentation. As a side, we also sought to examine the
skeletal muscle mRNA response to PA and/or WPC in-
gestion in an exploratory manner given that no infor-
mation to our knowledge exists on how PA ingestion
affects the skeletal muscle transcriptomic response. To
this end, and independent of mTOR signaling and MPS,
we examined key genes involved in muscle mass main-
tenance [myostatin (Mstn) and p21Cip1], metabolism
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(PGC-1α and GLUT-4), and skeletal muscle atrophy
(Atrogin-1 and MuRF-1) in an exploratory manner to
examine if PA with or without whey protein affected
these markers.
Methods
Animals and feeding protocols
All experimental procedures described herein were ap-
proved by Auburn University’s Institutional Animal Care
and Use Committee (protocol# 2013–2378). Male Wistar
rats (~250 g) were purchased from Harlan Laboratories
and were allowed to acclimate in the animal quarters for
5 days prior to experimentation. Briefly, animal quarters
were maintained on a 12 h light: 12 h dark cycle, at am-
bient room temperature, and water and standard rodent
chow (18.6 % protein, 44.2 % carbohydrate, 6.2 % fat; Tek-
lad Global #2018 Diet, Harlan Laboratories, Indianapolis,
IN, USA) was provided to animals ad libitum.
The day prior to the acute feeding experiments, food
was removed from home cages resulting in an 18 h over-
night fast. The morning of experimentation, animals
were removed from their quarters between 0800–0900,
transported to the Molecular and Applied Sciences La-
boratory and were allowed to acclimate for approxi-
mately 3–5 h. Thereafter, rats were gavage-fed either:
1) CON: 1 ml of tap water
2) PA: 0.029 g soy-derived PA (S-PA, Mediator®, Chemi
Nutra, Austin, TX, USA) suspended in 1 ml of tap
water; this being a human equivalent dose of 1.5 g
per the species conversion calculations of Reagan-
Shaw et al. [15]
3) WPC: 0.193 g WPC (standardized to 80 %, donated
graciously by C.M.L.) suspended in 1 ml of tap
water; this being a human equivalent dose of 10 g
4) PA +WPC: 0.029 g soy-derived PA + 0.193 g WPC
suspended in 1 ml of tap water
Of note, select data from group #3 above (WPC)
published as control group in a previously published
study by our group [16], but was used as a reference to
examine how PA and PA +WPC affected post-feeding
markers of muscle anabolism relative to WPC alone. It
should also be noted that, while a 10 g human equiva-
lent dose may be considered too low with regards to
being able to increase skeletal muscle MPS given that
10 g of WPC delivers ~1 g of leucine to humans, we
have consistently observed this dose of whey protein to in-
crease MPS in rat skeletal muscle in pilot experiments
(Additional file 1: Figure S1 in Mobley et al. [16]) as well
as previously published data [16].
The gavage feeding procedure involved placing the an-
imals under light isoflurane anesthesia for approximately
1 min while gavage feeding occurred. Following gavage
feeding, rats were allowed to recover 180 min prior to
being euthanized under CO2 gas. Of note, animals
were injected (i.p.) with puromycin dihydrochloride
30 min prior to euthanasia (5.44 mg in 1 ml of diluted
in phosphate buffered saline; Ameresco, Solon, OH,
USA) to determine skeletal MPS levels via the SUnSET
method [17].
Immediately following euthanasia, approximately two
50 mg pieces of mixed gastrocnemius muscle were har-
vested using standard dissection techniques and placed
in RIPA buffer [Tris base; pH 8.0, NaCl, NP-40, sodium
deoxycholate, SDS with added 1x protease (Ameresco)
and 1x phosphatase II and III inhibitors (G BioSciences,
St. Louis, MO, USA)] and Ribozol (Ameresco) for im-
munoblotting and mRNA analyses, respectively. Gastrocne-
mius samples placed in radioimmunoprecipitation assay
(RIPA) buffer were homogenized immediately upon ex-
traction using a micropestle, insoluble proteins were
removed with centrifugation at 500 xg for 5 min, and
supernatants were assayed for total protein content
using a BCA Protein Assay Kit (Thermo Scientific,
Waltham, MA, USA) prior to immunoblotting sample
preparation. Gastrocnemius samples placed in Ribozol
were subjected to total RNA isolation according to
manufacturer’s instructions, and RNA concentrations
were measured with a NanoDrop Lite (Thermo Scientific)
prior to cDNA synthesis for mRNA analyses. Extra
gastrocnemius muscle not processed during dissections
was flash-frozen in liquid nitrogen and stored at −80 °C
for later potential analyses.
Directed Akt-mTOR phosphoproteomics
The PathScan® Akt Signaling Antibody Array Kit (Chemi-
luminescent Readout; Cell Signaling, Danvers, MA, USA)
containing glass slides spotted with antibodies was utilized
to detect phosphorylated proteins predominantly belong-
ing to the Akt-mTOR signaling network.
Briefly, gastrocnemius homogenates were diluted to
0.5 μg/μl using cell lysis buffer provided by the kit and
assayed according to manufacturer’s instructions. Slides
were developed using an enhanced chemiluminescent
reagent provided by the kit at 1 min exposure times for
all chips, and spot densitometry was performed through
the use of a UVP Imager and associated densitometry
software (UVP, LLC, Upland, CA, USA). The calculation
of each phosphorylated target was as follows:
(Density value of the target – density of negative con-
trol) / between-sample normalizing factor (which was
the summation of all density values on the Chip for a
given sample).
It should be noted that this high throughput antibody
chip array for muscle phosphorylation markers was
used rather than single antibodies due to resource con-
straints. Moreover, others in the literature have used
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chemiluminescent-based phosphoarray chips for screening
purposes as we have utilized them herein [18, 19]. Fi-
nally, prior publications from our laboratory using this
method has shown that different doses of whey protein
feedings in rats increases p-rps6, p-mTOR, and
p-p70sk6 (Additional file 1: Figure S1 in Mobley et al.
[16]), and these arrays are sensitive at detecting differ-
ences in phospho-signaling events that occur in rodents
in response to cardiac ischemia-reperfusion [20].
Western blotting
As mentioned prior, the SUnSET method was employed
in order to examine if different dietary blends differen-
tially affected MPS. Briefly, gastrocnemius RIPA homog-
enates were prepared for Western blotting using 4x
Laemmli buffer at a concentration of 2 μg/μl. Thereafter,
20 μl of prepped samples were loaded onto pre-casted
12 % SDS-polyacrylamide gels (Bio-Rad, Hercules, CA,
USA) and subjected to electrophoresis (60 min @ 200 V).
Proteins were then transferred (120 min @ 200 mAmps)
to polyvinylidene difluoride membranes, and membranes
were blocked for 1 h at room temperature with 5 % nonfat
milk powder in Tris-buffered saline + Tween-20 (TBST).
For muscle samples, mouse anti-puromycin IgG (clone
12D10, 1:5,000; Millipore-Merck KGaA, Darmstadt,
Germany) was incubated with membranes overnight at
4 °C in 5 % bovine serum albumin (BSA) in TBST, and
the following day membranes were incubated with anti-
mouse IgG secondary antibodies (1:2,000, Cell Signaling,
Danvers, MA, USA) at room temperature for 1 h prior
to membrane development described below. Thereafter,
membranes were stripped of antibodies via commercial
stripping buffer (Restore Western Blot Stripping Buffer,
Thermo Scientific), membranes were then re-blocked
as described above and incubated with rabbit anti-beta-
actin (1:5,000; GeneTex, Inc., Irvine, CA, USA) as a
normalizer protein overnight at 4 °C in 5 % BSA in TBST,
and the following day membranes were incubated with
anti-rabbit IgG secondary antibodies (1:2,000; Cell Signal-
ing) at room temperature for 1 h prior to membrane
development.
Membrane development was performed using an en-
hanced chemiluminescent reagent (Amersham, Pittsburgh,
PA, USA), and band densitometry was performed through
the use of a gel documentation system and associated
densitometry software (UVP, Upland, CA, USA).
Real-time RT-PCR
Gastrocnemius RNA was obtained using Ribozol
(Ameresco, Solon, OH, USA) per the manufacturer’s
recommendations. Total RNA concentrations as well as
RNA purity (260/280 OD ratio > 1.8) were analyzed
using a Nanodrop Lite spectrophotometer (Thermo
Scientific, Waltham, MA, USA), and 1 μg of cDNA was
synthesized using a commercial qScript™ cDNA Super-
Mix (Quanta Biosciences, Gaithersburg, MD, USA)
per the manufacturer’s recommendations. Following
cDNA synthesis the resultant cDNA was diluted to
5 ng/μl using RNase-free water. Real-time PCR was
performed using SYBR-green-based methods with gene-
specific primers designed using primer designer software
(Primer3Plus, Cambridge, MA, USA). The forward and re-
verse primer sequences are as follows: [Myostatin (Mstn):
forward primer 5′- ACGCTACCACGGAAACAATC −3′,
reverse primer 5′- CCGTCTTTCATGGGTTTGAT −3′;
p21Cip1: forward primer 5′- AGCAAAGTATGCCGTC
GTCT −3′, reverse primer 5′- ACACGCTCCCAGACGT
AGTT −3′; Atrogin-1: forward primer 5′-CTACGATGT
TGCAGCCAAGA −3′, reverse primer 5′- GGCAGTCGA
GAAGTCCAGTC −3′; Muscle RING finger protein-
1(MuRF-1): forward primer 5′- AGTCGCAGTTTCGAA
GCAAT-3′, reverse primer 5′- AACGACCTCCAGACA
TGGAC-3′; Glucose transporter-4 (Glut-4): forward pri-
mer 5′-GCTTCTGTTGCCCTTCTGTC −3′, reverse pri-
mer 5′- TGGACGCTCTCTTTCCAACT −3′; Peroxisome
proliferator-activated receptor gamma coactivator 1-alpha
(Pgc-1α): forward primer 5′- ATGTGTCGCCTTCTTGC
TCT- 3′, reverse primer 5′- ATCTACTGCCTGGGGAC
CTT −3′; β2-microglobulin (B2M; housekeeping gene):
forward primer 5′- CCCAAAGAGACAGTGGGTGT - 3′,
reverse primer 5′- CCCTACTCCCCTCAGTTTCC -3’]
and SYBR green chemistry (Quanta). Fold-change values
from the water (fasting) treatment were performed using
the Livak method (i.e., 2-ΔΔCT assuming 100 % primer
binding efficiency), where 2-ΔCT = [housekeeping gene
CT – gene of interest CT] and 2-ΔΔCT (or fold-
change) = [2-ΔCT value/2-ΔCT average of water (fast-
ing) treatment]. Primer efficiency curves for all genes
were generated and efficiencies ranged between 90 %
and 110 %.
Cell culture
C2C12 myoblasts (ATCC; Manassas, Virginia) were
plated at approximately 40 % confluence and grown for
24 h in 10 % FBS High Glucose DMEM with antibiotics
(100 μg/ml streptomycin and 100 U/ml penicillin;
Sigma). At 18 h prior to the experiment, the myoblasts
were switched to serum free high glucose DMEM (no
antibiotics) and were approximately 90 % confluent at
the time of the experiment. As detailed previously, the
myoblasts were then stimulated with 30 μM of soy-
derived PA (S-PA, Mediator®, Chemi Nutra, Austin, TX,
USA) or PBS as a control condition [12]. For measure-
ments of mTOR signaling, myoblasts were collected at
30 min after stimulation. For measurements of protein
synthesis, 1 μM puromycin was added to the media
during the final 30 min of a 60 min stimulation period,
as previously described [17]. In all cases, myoblasts
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were collected in an ice-cold lysis buffer consisting of
(40 mM Tris, pH 7.5; 1 mM EDTA; 5 mM EGTA; 0.5 %
Triton X-100; 25 mM β-glycerophosphate; 25 mM NaF;
1 mM Na3VO4; 10 μg/mL leupeptin; and 1 mM PMSF)
and then centrifuged at 500 x g for 5 min. The resulting
supernatants were then subjected to Western blot ana-
lyses for puromycin, total p70s6k and phosphorylated
p70s6k (Thr389) as detailed previously [12].
Statistics
All data are presented as means ± standard error. For in
vivo data, statistics were performed between treatments
using an ANOVA with protected LSD post hoc compar-
isons when applicable in order to avoid an inflated type
I error rate. For in vitro data, treatment comparisons
were made using independent samples t-tests. All
statistics were performed using IBM SPSS version 22.0
and significance was determined at p < 0.05.
Results
PA and PA +WPC increase 3 h post-feeding
phosphorylation of select mTOR pathway substrates
There was no difference in p-Akt (Ser473) between treat-
ments (p > 0.05; Fig. 1a). Compared to CON, phosphory-
lated p-mTOR (Ser2481), which is a marker of mTOR
autophosphorylation and activation [21], was approxi-
mately 2-fold higher in PA and PA +WPC rats (p < 0.05;
Fig. 1b), though there was no difference in this marker be-
tween the latter two groups. Compared to CON, PA and
PA +WPC led to a paradoxical decrease in p-4EBP1
(Thr37/46) (p < 0.05; Fig. 1c). Compared to CON, p-
p70s6k (Thr389) was ~80 % higher in PA +WPC rats
(p < 0.05; Fig. 1d), whereas other treatments did not
statistically differ from CON. Compared to CON, p-
rps6 (Ser235/236) was approximately 2.3–3.1-fold
higher in PA and PA +WPC rats (p < 0.05; Fig. 1e),
though again there was no difference in this marker be-
tween the latter two groups.
PA and/or PA +WPC minimally affect 3 h post-feeding
phosphorylation of other substrates related to protein
synthesis
All treatments equally affected the phosphorylation sta-
tus of AMPK-α (Thr172), Erk (Thr202/Tyr204), PDK1
(Ser241), and PRAS40 (Thr246) (Fig. 2). Interestingly,
PA increased p-GSK-3α (Ser21) 60 % compared to
CON (p < 0.05; Fig. 2d). As reported previously [22], WPC
increased the phosphorylation of GSK-3α/β (Fig. 2d & e),
though PA +WPC interestingly exacerbated this response
compared to WPC alone.
Effects of PA and PA +WPC on 3 h post-feeding
MPS levels
Of note, WPC rats have been used in a prior study
whereby we reported the significant two-fold increase in
MPS relative to CON [22]. However, in the current study
samples were re-run and normalized to Ponceau staining
instead of beta-actin normalization given that mixed
gastrocnemius fiber types may potentially yield varying
normalization values. As expected, WPC robustly in-
creased MPS levels compared to CON rats confirming
our prior data. Compared to CON rats, MPS trended to
be higher in PA-fed rats (p = 0.08; Fig. 3). Interestingly,
however, PA +WPC-fed rats exhibited lower MPS
levels compared to WPC-fed rats (p < 0.05, Fig. 3).
Fig. 1 Effects of PA with or without the co-ingestion of WPC on mTOR signaling markers. Legend: Data are presented as means ± standard error,
and bars not sharing similar superscript letters are significantly different (p < 0.05) as determined by one-way ANOVAs with protected LSD post
hoc comparisons. CON n-size = 13, PA, WPC, and PA +WPC n-sizes = 7–8. Panels a–e: Effects of each ingredient on upstream positive modulators
of protein synthesis. Panel f: representative digital images select phospho-targets that were altered with feedings
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In vitro confirmation that PA increases MPS and mTOR
signaling
p-p70s6k (Thr389) increased 67 % in 30 min PA-treated
myoblasts compared to the control condition (p < 0.001;
Fig. 4a). Moreover, MPS levels were increased 51 % in
60 min PA-treated myoblasts compared to the control
condition (p < 0.001; Fig. 4b). These data further validate
the aforementioned in vivo results suggesting that the
soy-derived PA studied herein increases mTOR signaling
and likely increases MPS.
Fig. 2 Effects of PA with or without the co-ingestion of WPC on other intramuscular signaling markers. Legend: Data are presented as means ±
standard error. Bars not sharing similar superscript letters are significantly different (p < 0.05) as determined by one-way ANOVAs with protected
LSD post hoc comparisons. CON n-size = 13, PA, WPC, and PA +WPC n-sizes = 7–8. Panel a: Effects of each ingredient on AMPK-α phosphorylation
3 h post-ingestion (cellular energy sensor; more phosphorylation is related to decreased mTOR pathway activation). Panel b: Effects of each ingredient on
Erk-1/2 phosphorylation 3 h post-ingestion (positive upstream modulator of protein synthesis). Panel c: Effects of each ingredient on PDK1 phosphorylation
3 h post-ingestion (upstream modulator of protein synthesis). Panel d & e: Effects of each ingredient on GSK-3α/β phosphorylation 3 h post-
ingestion (upstream modulator of protein synthesis). Panel f: Effects of each ingredient on PRAS40 phosphorylation 3 h post-ingestion (negative upstream
modulator of protein synthesis)
Fig. 3 Effects of PA with or without the co-ingestion of WPC on 3 h post-feeding MPS. Legend: Data are presented as means ± standard error,
and bars not sharing similar superscript letters are significantly different (p < 0.05) as determined by one-way ANOVAs with protected LSD post
hoc comparisons. CON, PA, WPC, and PA +WPC n-sizes = 6–8. Panel a: Effects of each treatment on 3 h post-feeding MPS levels. Panel b: Representative
image of the SUnSET blot. PA, WPC, and PA +WPC all significantly increased MPS levels compared to fasting conditions
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PA and PA +WPC increase select 3 h post-feeding mRNAs
related to skeletal muscle anabolism and metabolism
Beyond examining the effects that PA with or without
WPC exhibited on mTOR signaling and MPS, we also
were interested in prospectively exploring if these treat-
ments acutely affected gene expression patterns related
to skeletal muscle mass regulation and metabolism.
Interestingly, PA or WPC did not cause a change in
Mstn mRNA compared to CON, though PA +WPC
rats presented statistically lower Mstn mRNA levels
relative to the PA- and WPC-fed rats (p < 0.05; Fig. 5a);
however, Mstn mRNA in WPC + PA did not change
compared to the control group. Compared to CON, PA
robustly increased p21Cip1 mRNA expression patterns
over 5.6-fold (p < 0.05, Fig. 5b). Likewise, compared to
CON, WPC and PA +WPC increased p21Cip1 mRNA
expression over 3-fold, though this only tended to be
greater than fasting (p < 0.10) due to the high post-
feeding variation in this transcript. No between-group
differences existed in PGC-1α mRNA levels (Fig. 5c).
Compared to CON, PA increased Glut-4 mRNA levels
43 % (p < 0.05; Fig. 5d) and PA +WPC increased Glut-4
mRNA expression patterns ~60 % (p < 0.05, Fig. 5d). All
treatments presented similar Atrogin-1 mRNA levels
(Fig. 5e). Finally, PA +WPC increased MuRF-1 mRNA
2.3-fold relative to CON (p < 0.05, Fig. 5f ).
Discussion
This is the first study to demonstrate that PA, with or
without WPC, increases the post-feeding phosphoryl-
ation of select skeletal muscle mTOR pathway sub-
strates, and PA tends to increase MPS levels in vivo.
Moreover, our in vitro data demonstrate that exogen-
ous PA administration increases mTOR signaling and
MPS in C2C12 myoblasts. These data complement the
two human studies suggesting that 8 weeks of PA sup-
plementation increases skeletal muscle mass [11, 12].
These findings are discussed in greater detail below.
PA, with or without WPC, increases post-feeding mTOR
pathway activity in vivo
Our findings that PA, with or without WPC co-ingestion,
increases post-feeding mTORC1 pathway activity and
MPS in vivo supports other mechanistic literature
examining the effects of PA on these variables. For in-
stance, Fang et al. [5] treated HEK293 cells with PA
and the authors demonstrated that: a) p70s6k activity
increased; b) rapamycin (an mTOR inhibitor) blunted
PA-induced increases in p70s6k activity; c) blunting
serum-induced PA production in HEK293 cells with 1-
butanol reduced p70s6k activity; and d) PA has a high
binding affinity for mTOR on the FRB rapamycin-
sensitive domain which, upon binding, increases the
Fig. 4 PA increases C2C12 myoblast mTOR signaling and MPS. Legend: Data are presented as means ± standard error. All data were obtained from
2–3 independent experiments (n = 6–11 wells per condition). Significant between-treatment differences (p < 0.001) existed for p-p70s6k (Thr389)
and MPS levels as determined by independent samples t-tests (denoted by different superscript letters). Panel a: C2C12 myoblasts were serum
starved for 18 h and then stimulated for 30 min with 30 μM PA, or PBS as a control condition. Measurements of mTOR signaling were assessed
by evaluating the phospho to total ratio (P:T) for p-p70s6k (Thr389) and total p70S6k. Panel b: C2C12 myoblasts were treated as described in panel
a and measurements of protein synthesis were performed by assessing puromycin incorporation during the final 30 min of a 60 min stimulation
period. The Western blot membranes were stained with Coomassie Blue to verify equal loading of protein in all lanes
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phosphorylation of mTOR-dependent substrates such
as p70s6k (Thr389). The aforementioned study also
demonstrated that PA levels in HEK293 cells had no
effect on p-Erk1/2 (Thr202/Tyr204) or p-Akt (Ser473)
levels.
The effects of PA in rat skeletal muscle presented
herein are in agreement with the aforementioned data.
Specifically, we demonstrated that: a) PA or PA +WPC
did not alter 3 h post-feeding p-Akt (Ser473) or p-
Erk1/2 (Thr202/Tyr204) levels relative to CON; and b)
PA and PA +WPC increased p-mTOR (Ser2481) levels,
as well as p-rps6 (Ser235/236) relative to CON. Fur-
thermore, our in vivo data demonstrates that PA tended
to increase MPS and PA +WPC significantly increased
MPS levels relative to CON. However, it is interesting
that, while WPC increased MPS the greatest, PA +
WPC did not synergistically increase MPS levels in
spite of the fact that p-p70s6k (Thr389) and p-rps6
(Ser235/236) were numerically the greatest in the com-
bined fed group relative to PA and WPC alone. In this
regard, we speculate that one of two phenomena are
occurring: a) combined PA and WPC may alter the
mTOR pathway activation dynamics relative to WPC-
induced mTOR activation and, thus, peak MPS levels
are shifted to the right or left of the 3 h post-feeding
sampling point taken in the current study; or b) PA
may actually interfere with WPC-induced increases in
MPS. With regards to the latter point, PA and PA +
WPC rats presented decreased levels of p-4EBP-1 rela-
tive to CON; this being a potential mechanism whereby
PA may have ‘interfered’ with WPC-induced increases
in MPS. This finding is difficult to reconcile as in vitro
investigations have demonstrated that PA treatment
[14] or inhibition of PA production [5] results in the
increased and decreased phosphorylation of 4EBP-1, re-
spectively. Thus, it will be of future interest to examine
how PA and PA +WPC affect mTORC1 signaling,
namely 4EBP-1 phosphorylation, and MPS levels over
multiple post-feeding time points in vivo.
PA, with or without WPC, differentially affect post-feeding
skeletal muscle mRNAs related to anabolism and
metabolism
Of the mRNA alterations that occurred with PA and/or
PA +WPC, our major findings include: a) PA led to a ro-
bust post-feeding increase in p21Cip1 mRNA expression
relative to CON; b) PA and PA +WPC led to a signifi-
cant increase in Glut-4 mRNA expression relative to
CON; and c) PA +WPC led to a significant increase in
MuRF-1 mRNA expression relative to CON.
p21Cip1 gene expression is thought to promote sat-
ellite cell differentiation [23, 24], though others have
Fig. 5 Effects of PA with or without the co-ingestion of WPC on skeletal muscle mRNA expression patterns. Legend: Data are presented as means ±
standard error. Bars not sharing similar superscript letters are significantly different (p < 0.05) as determined by one-way ANOVAs with protected LSD
post hoc comparisons. CON n-size = 13, PA, WPC, and PA +WPC n-sizes = 7–8. Panels a & b: Genes linked to skeletal muscle hypertrophy. Panels c & d:
Genes linked to skeletal muscle metabolism. Panels e & f: Genes linked to skeletal muscle atrophy (Atrogin-1) and remodeling (MuRF-1)
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shown that p21Cip1 gene expression is linked to pro-
tein synthesis and hypertrophy in post-mitotic kidney
epithelial cells [25]. Furthermore, we [26] and others
[27] have shown a 1–6 h robust increase in p21Cip1
mRNA expression after an acute bout of resistance ex-
ercise which suggests that this gene is being expressed
from post-mitotic muscle fibers rather than differenti-
ating satellite cells. Hence, it remains plausible that
mTORC1 pathway activation may be linked to the
mRNA expression of p21Cip1 which, in turn, may be
related to enhanced translational mechanisms; this be-
ing a hypothesis which we have posited previously
[28]. In support of this hypothesis, Nader et al. [29]
have shown that mTOR increases the expression of cell
cycle-related genes in post-mitotic myotubes in order
to enhance ribosomal biogenesis. Therefore, it will be
of further interest to examine if chronic PA supplemen-
tation leads to an increase in intramuscular markers of
ribosome biogenesis, whether this effect is mitigated
through an enhanced p21Cip1 gene expression, and
whether this potential effect is causally-related to muscle
hypertrophy evident with longer-term supplementation.
Our finding that PA +WPC ingestion increased MuRF-1
mRNA expression relative to CON is intriguing. While
amino acids are anti-catabolic [30], other literature has
shown that protein ingestion increases the mRNA ex-
pression of MuRF-1 mRNA in human skeletal muscle
after resistance exercise [31, 32]. Conversely, skeletal
muscle MuRF-1 mRNA as well as markers of muscle pro-
tein synthesis has been reported to be lower in spinal-
cord-injured patients [33]; a finding which the authors
suggest is linked to the tight regulation of muscle protein
breakdown and synthesis rates. Thus, the results in the
current study suggesting that PA +WPC ingestion in-
creases the mRNA expression of MuRF-1 may represent a
stimulation of greater muscle protein turnover (i.e., in-
creased synthesis paralleled with increased breakdown
rates) rather than an increase in atrophic mechanisms.
Finally, our finding that PA and PA +WPC modestly
increased post-feeding Glut-4 mRNA is intriguing given
the potential that this may be a manner whereby PA
supplementation could potentially increase glucose sen-
sitivity in an mTOR-dependent manner. To this end,
insulin-like growth factor-1, a known activator of the
mTORC1 signaling cascade, has been shown to increase
Glut-4 mRNA in vitro [34]. Recent evidence also sug-
gests that six weeks of cycling increases type II muscle
fiber Glut-4 protein levels which were co-incident with
increases in p-mTOR levels [35]. Thus, there seems to
be interplay between mTORC1 activation and Glut-4
gene expression. To this end, it will be of further interest
to examine if PA supplementation is capable of affecting
serum glucose levels in rodent models or human popula-
tions with impaired glucose tolerance.
Conclusions
In summary, this is the first study to demonstrate that PA,
with or without WPC co-ingestion, increases mTORC1
pathway activation. Furthermore, these data demonstrate
that PA ingestion tends to increase MPS levels in vivo
relative to the fasted condition. While these findings are
novel, this study is not without its limitations including: a)
the limited post-feeding time point interrogation, b) the
lack of intramuscular PA data, and c) the absence of other
PA and/or WPC dosages as well as the lack of an exercise
stimulus. With regards to the limitation ‘b’, we attempted
to use a commercial fluorometric assay to measure muscle
PA levels, but we did not have confidence in the data due
to the high background fluorometric signal that the assay
buffer possessed. With regard to the last limitation, future
studies are needed in order to examine if: a) pre-loading
with PA and/or higher doses of PA further promotes skel-
etal muscle anabolism, and b) if higher doses of PA in an
acute exercise setting facilitates greater increases in MPS
relative to the dose used herein. To this end, mechanistic
rat studies in our lab using a hind limb stimulation model
of resistance exercise has proven to be effective for in-
creasing MPS in the fasted state (unpublished observa-
tions) and, thus, this model could be a valuable tool that
continues to explore the efficacy of PA in enhancing post-
exercise skeletal muscle anabolism. Given that mTORC1
pathway activation is integral in myoblast proliferation
[36] and differentiation [37], examining how PA supple-
mentation with resistance training affects myonuclear do-
main size, myonuclear number and satellite cell number is
also warranted. It should also be noted that serum was
not obtained from these animals and, given that Glut-4
mRNA transiently increases in PA-fed rats, future re-
search should examine how dietary PA effects the post-
prandial hormonal milieu (i.e., potential PA-mediated
increases in insulin). Finally, the potential metabolic ef-
fects of PA supplementation beyond skeletal muscle
hypertrophy (i.e., the effects of PA supplementation on
glucose tolerance and/or appetite given that hypothal-
amic mTORC1 activation is anorectic [38]) may unveil
PA as a nutraceutical candidate in populations beyond
resistance-trained athletes.
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